Benralizumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nasal Polyps
Conditions
Nasal Polyps
Trial Timeline
Feb 24, 2020 → Jun 28, 2024
NCT ID
NCT04185012About Benralizumab + Placebo
Benralizumab + Placebo is a phase 3 stage product being developed by AstraZeneca for Nasal Polyps. The current trial status is completed. This product is registered under clinical trial identifier NCT04185012. Target conditions include Nasal Polyps.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05692180 | Phase 3 | Recruiting |
| NCT05251909 | Phase 3 | Terminated |
| NCT04612790 | Phase 3 | Terminated |
| NCT04191304 | Phase 3 | Active |
| NCT04185012 | Phase 3 | Completed |
| NCT03953300 | Approved | Active |
| NCT04053634 | Phase 3 | Completed |
| NCT03470311 | Phase 3 | Completed |
| NCT03473977 | Phase 2/3 | Completed |
| NCT03186209 | Phase 3 | Completed |
| NCT02322775 | Phase 3 | Completed |
| NCT01947946 | Phase 3 | Terminated |
| NCT01928771 | Phase 3 | Completed |
| NCT01914757 | Phase 3 | Completed |
Competing Products
20 competing products in Nasal Polyps